Cellular reprogramming is the most ambitious rejuvenation claim in the field because it targets cell state itself rather than one downstream pathway.
The excitement is rational. Partial reset programs now show enough preclinical signal that dismissal is no longer a serious position. The hard question has shifted to control architecture: delivery, shutdown, tissue specificity, and identity preservation.
These articles track that narrower and more useful question. Instead of asking whether reprogramming is conceptually possible, they examine whether current strategies can remain inside a therapeutic operating window without drifting into cancer risk, dedifferentiation, or unstable effects.
That frame is also the right one for discovery readers. A platform can be real while the human deployment case remains early. The relevant distinction is between mechanistic possibility and clinically governable medicine.
